OPTR and TSRX aren't they similar? I saw some one comparing the two here.
It seems the market potential of the TSRX drug is at least as good if not better than the OPTR drug, yet OPTR's market cap is now double that of TSRX. It will take time, but lots of room for TSRX to run.
Both antibiotics and small enough to be easily acquired. The OPTR news should provide a big boost to TSRX, should be at least $7+ on this news IMO.